Abstract
Background: Neoadjuvant therapy (NT) has increasingly gained popularity over upfront surgery for pancreatic adenocarcinoma (PDAC). Within this conceptual framework, administration of the complete chemotherapy course prior to surgery is considered optimal. This notion of “total” application of anti-oncologic therapy – so far referred to as Total Neoadjuvant Therapy (TNT) – appears to be, hitherto, an amalgam of different definitions, regimens and timing uniquely ascribed and executed by individual institutions. This review critically examines TNT’s reported efficacy for pancreatic cancer with an aim towards improving standardization of its nomenclature and clinical application.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
